Dr. Shaker A. Mousa to Test New Approaches to Stop the Spread of Pancreatic
ALBANY, N.Y., June 26 /PRNewswire/ -- Shaker A. Mousa, Ph.D., executive vice president and chairman of the Pharmaceutical Research Institute (PRI) at Albany College of Pharmacy (ACP), has been awarded a $368,445 research grant from the National Cancer Institute, part of the National Institutes of Health. Dr. Mousa along with a team of PRI investigators that includes Dr. Lawrence Lansing, Dr. Lakshman Sehgal, Dr. Murat Yalcin and PRI technical staff, will study new methods for limiting the spread of pancreatic cancer in the body to allow for better treatment of the disease. The research will take place over a period of 22 months.
Cancer cells survive and spread (metastasize) by attaching themselves to platelets in the bloodstream. Research has shown that the blood thinner Heparin is effective in preventing the bonding of cancer cells and platelets, but the dosages required to affect this result lead to increased bleeding or blood loss in patients. Dr. Mousa and his team will focus their research on modifying 'low molecular weight Heparin compounds' in a way that will still inhibit the bonding of the cancer cells and platelets, while minimizing or eliminating the bleeding and other negative side effects associated with high levels of Heparin.
"Pancreatic cancer is not only hard to diagnose, but it is an extremely
aggressive form of cancer. Surgeons rarely operate on patients with
pancreatic cancer when metastasis is taking place as the surgery tends to
accelerate the spread of the cancer," said Dr. Mousa. "If we can keep the
cancer cells from attaching to the platelets, we can isolate them in the
body. They can then be killed fairly easily by the patient's own immune
system or through low levels of chemotherapy. Once that happens, physicians
will have a significantly better opportunity to treat the cancer and extend
|SOURCE Albany College of Pharmacy|
Copyright©2008 PR Newswire.
All rights reserved